Gemeinschaft SantEgidio Access to Treatment in Africa Ergebnisse und Herausforderungen aus dem Programm DREAM Dieter Wenderlein Gemeinschaft SantEgidio.
Navin presentation for hiv disease
Pharmacogenomics of HIV Therapy
The Merits of Monotherapy For HIV - Key Study Results in PI Monotherapy, Dr Jose R Arribas
PR Excellence_Malaysia Convention & Exhibition Bureau
Highlights of IAS 2013.CCO Official Conference Coverage of the 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention
« Decentralization of HIV care in subsaharan Africa: lessons for resource allocation» Dr. Fred Eboko, IRD French Research Institute for the Development,
1 Efficacy and safety of switching from boosted Lopinavir (LPV/r) to boosted Atazanavir (ATV/r) in patients with virologic suppression receiving a LPV/r.
Long-term ART initiated during primary HIV-1 infection limits the HIV-1 reservoir size but not to levels found in LTNPs Eva Malatinkova, Ward De Spiegelaere,
HIV Drug Resistance in sub-Saharan Africa Experiences with PASER Prof Tobias Rinke de Wit Wednesday, November 20, 2013 Bloemfontein, South Africa.
Yves BENHAMOU. Management of Patients with HIV/HBV Co-infection Yves Benhamou Hepatology Department Groupe Hospitalier Pitié Salpétrière Paris, France.
Are we most likely to cure HIV with gene therapy? Sharon R Lewin Director, Infectious Disease Unit, Alfred Hospital Professor, Department of Medicine,